Holen Sie sich die Stockscreener-App
0.7717
4.42%
-0.0357
Handel nachbörslich:
.78
0.0083
+1.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Lexicon: Q3 Earnings Snapshot - The Washington Post
FMR LLC's Strategic Acquisition of Lexicon Pharmaceuticals Shares - GuruFocus.com
LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings: EPS of -$0. - GuruFocus.com
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Previ - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | LXRX Stock News - StockTitan
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga
HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times
Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter
Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch
Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com
FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive
Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline News & Insights
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista — Update - Morningstar
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):